Vabysmo®
Faricimab is the first bispecific antibody for intraocular use, simultaneously targeting VEGF-A and Ang-2. Allows extended dosing intervals up to 16 weeks.
| Dosage Form | Intravitreal Injection (Solution) |
| Strength | 6 mg/0.05mL |
| Storage | Store at 2–8°C. Do not freeze. Protect from light. |
| Category | Ophthalmics |
| Availability | Available for Transfer |
Wet AMD; diabetic macular edema.
Bispecific antibody that independently binds and neutralizes both VEGF-A and angiopoietin-2 (Ang-2). Dual pathway inhibition stabilizes vasculature, reduces inflammation, and allows longer treatment intervals.
Each Burrard Pharmaceuticals technology transfer package for Faricimab includes comprehensive documentation and support:
Complete formulation with manufacturing parameters, excipient specifications, and process controls.
Validated methods for assay, impurities, dissolution, and stability-indicating analysis.
Market-ready regulatory dossier sections for a named territory, scoped per programme.
ICH-compliant stability studies (accelerated and long-term) with detailed protocols.
Scale-up procedures, batch records, equipment specifications, and in-process controls.
Direct advisory access to formulation scientists and regulatory specialists throughout transfer.
Scope and timing for the complete know-how package are confirmed in writing after a confidentiality agreement. Book a consultation to discuss your specific requirements.